Virtual Library
Start Your Search
C. Olier
Author of
-
+
P2.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 207)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Advanced Diseases - NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P2.01-056 - Thyroid Transcription Factor 1 (TTF1) as a Possible Predictive Biomarker for Pemetrexed-Based Chemotherapy in Non-Squamous NSCLC (ID 1740)
09:30 - 09:30 | Author(s): C. Olier
- Abstract
Background:
There are no demonstrated predictive molecular markers for pemetrexed. The aim of this study is to explore and evaluate whether thyroid transcription factor 1 (TTF1) protein expression can be a predictive biomarker of clinical activity for pemetrexed-based chemotherapy in patients with nonsquamous non-small cell lung cancer (NSCLC).
Methods:
123 patients with advanced nonsquamous NSCLC treated with pemetrexed-based chemotherapy as first-line, maintenance, second or later-line therapy were retrospectively reviewed. Then we chosen patients who had undergone assay of immunohistochemical expression of TTF1 in their tumor tissue sample, and we analyzed for their clinicopathological features, expression of TTF1 and clinical outcomes. Analysis of TTF1 expression was done according to the routine clinical practice of our center.
Results:
Immunohistochemical analysis of TTF1 expression was only performed in 51 of the 123 patients reviewed. Of these 51 patients, 36 were men and 15 women, 7 (13,7%) had never smoked and 44 (86,3%) were former or current smokers. Median age was 65 (range 39-79). Performance status (PS) distribution: 0 (25,4%), 1 (62,7%), 2 (7,8%), 3 (3,9%). Predominant histology type was adenocarcinoma (78,4%), followed by large cell carcinoma (13,7%) and not otherwhise specified-NOS (7,8%). 36 patientes had TTF1-positive tumors (70,5%), and 15 TTF1-negative ones (29,5%). The types of tumor tissue sample in which TTF1 assay was undergone were the following: endobronquial biopsy (43,1%), percutaneous biopsy (33,3%), fine needle aspiration puncture (17,6%), citology (0,5%). TTF1 positive tumors shown a higher disease control rate (DCR) for pemetrexed-based chemotherapy (60,5% vs 39,5%, p=0,05). Median progresión free survival (PFS) and overall survival (OS) in the whole group was 5,55 and 23,95 months respectively. TTF1-positive tumors had significant longer PFS (6,96 vs 3,64 months; p=0,0156) and a nonsignificant trend of longer OS (24,27 vs 13,66 months; p=0,581) to pemetrexed-based chemotherapy than patients with TTF1-negative tumors.
Conclusion:
TTF1 protein expression was associated with better clinical outcomes. TTF1 positive tumors shown a significant association with better PFS and a nonsignificant trend of better DCR and OS in nonsquamous NSCLC patients who were treated with pemetrexed-based chemotherapy. The predictive role of TTF1 expression should be further studied.
